HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Anaesthetics and muscle relaxants											
Bupivacaine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Cisatracurium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexmedetomidine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etidocaine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Halothane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isoflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ketamine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propofol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Remifentanil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rocuronium	△	△	△	△	■	■	◆	◆	△	△	◆
Sevoflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tetracaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thiopental	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tizanidine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Analgesics											
Aceclofenac	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alfentanil	◆	■	■	◆	■	■	◆	◆	◆	◆	◆
Aspirin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Buprenorphine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Celecoxib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Codeine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Dexketoprofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dextropropoxyphene	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Diamorphine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Diclofenac	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diflunisal	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dihydrocodeine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Etodolac	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etoricoxib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fentanyl (Prescribed)	◆	■	■	◆	■	■	◆	◆	◆	◆	◆
Flurbiprofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrocodone	◆	◆	■	◆	■	■	◆	◆	◆	◆	◆
Hydromorphone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ibuprofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indometacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ketoprofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mefenamic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Meloxicam	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Metamizole (Dipyrone)	■	■	△	◆	■	■	◆	◆	■	■	●
Methadone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Morphine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Naproxen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nefopam	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Oxycodone	◆	■	■	◆	■	■	◆	◆	◆	◆	◆
Paracetamol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pethidine (Meperidine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piroxicam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tapentadol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tramadol	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Anthelmintics											
Albendazole	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ivermectin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Niclosamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxamniquine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Praziquantel	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Pyrantel	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antiarrhythmics											
Amiodarone	●	■	■	●	●	●	◆	●	●	●	◆
Bepridil	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Digoxin	■	◆	■	■	■	■	◆	◆	■	■	◆
Disopyramide	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Dofetilide	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Dronedarone	●	■	■	●	●	●	◆	●	●	●	◆
Flecainide	◆	◆	◆	△	■	■	◆	◆	◆	◆	◆
Lidocaine (Lignocaine)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Mexiletine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propafenone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Quinidine	■	■	■	■	●	●	◆	◆	■	■	◆
Vernakalant	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Antibacterials											
Amikacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amoxicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ampicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azithromycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aztreonam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bedaquiline	◆	■	■	■	■	■	◆	◆	◆	◆	◆
Benzylpenicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bezlotoxumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Capreomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefaclor	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefadroxil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefalexin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefazolin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefixime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefotaxime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefradine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftaroline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftazidime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftriaxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chloramphenicol	△	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ciprofloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clarithromycin	■	◆	△	◆	●	●	◆	◆	◆	△	◆
Clavulanic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clindamycin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clofazimine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cloxacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cycloserine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dapsone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Daptomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Delamanid	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ertapenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erythromycin	◆	◆	■	◆	■	■	◆	◆	◆	■	◆
Ethambutol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flucloxacillin	△	△	△	△	△	△	△	△	△	△	◆
Fosfomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gatifloxacin (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gentamicin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imipenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isoniazid	△	△	△	△	△	△	◆	△	△	△	△
Levofloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Linezolid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Lymecycline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Meropenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methenamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metronidazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Minocycline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxifloxacin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Nitrofurantoin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norfloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ofloxacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Penicillin V	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piperacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pivmecillinam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pretomanid	◆	●	■	◆	△	△	◆	◆	◆	■	■
Pyrazinamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rifabutin	●	●	●	●	■	■	●	△	●	●	◆
Rifampicin	●	●	●	●	●	●	●	●	●	●	◆
Rifapentine	●	●	●	●	■	■	●	●	●	●	◆
Rifaximin	△	△	△	△	△	△	◆	◆	△	△	◆
Spectinomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Streptomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfadiazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tazobactam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telithromycin	■	■	■	■	●	●	◆	◆	◆	■	◆
Temocillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tetracyclines	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticarcillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tobramycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Troleandomycin	■	●	●	◆	■	■	◆	◆	■	●	◆
Vancomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Anticoagulant, anti-platelet and fibrinolytic											
Abciximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Acenocoumarol	■	■	■	■	■	■	■	■	■	■	◆
Anagrelide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Apixaban	△	△	△	△	■	■	◆	◆	△	△	◆
Caplacizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clopidogrel	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Dabigatran	■	■	●	■	■	■	◆	◆	■	●	◆
Dalteparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Danaparoid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Edoxaban	■	■	■	■	■	■	◆	◆	■	●	◆
Enoxaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluindione	◆	■	■	■	■	■	■	■	■	■	◆
Fondaparinux	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Natalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenprocoumon	■	■	■	■	■	■	■	■	■	■	◆
Prasugrel	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Rivaroxaban	■	■	■	■	●	●	◆	◆	■	■	◆
Streptokinase	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticagrelor	■	■	■	■	●	●	◆	◆	■	■	◆
Ticlopidine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Tinzaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Warfarin	■	■	■	■	■	■	■	■	■	■	■
Anticonvulsants											
Brivaracetam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Carbamazepine	■	●	■	■	●	●	●	■	■	●	◆
Clonazepam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Eslicarbazepine	■	●	■	◆	●	●	◆	◆	■	●	◆
Ethosuximide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lamotrigine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxcarbazepine	■	●	■	■	●	●	●	■	■	●	◆
Perampanel	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Phenobarbital	■	●	■	■	●	●	●	■	■	●	◆
Phenytoin	■	●	■	■	●	●	●	■	■	●	◆
Pregabalin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Primidone	■	●	■	■	●	●	●	■	■	●	◆
Retigabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Anticonvulsants continued											
Rufinamide	■	■	■	■	■	■	●	■	■	■	◆
Sodium valproate	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Tiagabine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valproate semisodium	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Valproic acid (Divalproex)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antidepressants											
Agomelatine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amitriptyline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bupropion	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Desipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desvenlafaxine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Dosulepin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Doxepin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Duloxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Escitalopram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imipramine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lithium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mianserin	◆	△	△	◆	■	■	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Moclobemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nefazodone	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Nortriptyline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Opipramol	◆	◆	◆	◆	△	△	◆	◆	◆	◆	■
Paroxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenelzine	●	●	●	●	●	●	●	●	●	●	●
Reboxetine	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Tianeptine	◆	■	■	■	■	■	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Venlafaxine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Antidiabetics											
Acarbose	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Albiglutide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alogliptin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Canagliflozin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Dapagliflozin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dulaglutide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Empagliflozin	◆	◆	◆	◆	◆	◆	◆	◆	■	■	◆
Exenatide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glibenclamide (Glyburide)	◆	◆	■	◆	■	■	◆	◆	◆	◆	◆
Gliclazide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Glimepiride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glipizide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Insulin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Linagliptin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Liraglutide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lixisenatide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metformin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nateglinide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pioglitazone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Repaglinide	■	◆	■	◆	■	■	◆	◆	△	■	◆
Rosiglitazone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Saxagliptin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Semaglutide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sitagliptin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tirzepatide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tolbutamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vildagliptin	◆	◆	△	◆	◆	◆	◆	◆	■	◆	◆
Antifungals											
Amphotericin B	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Anidulafungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Caspofungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clotrimazole (pessary)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clotrimazole (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluconazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flucytosine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Griseofulvin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Isavuconazole	△	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Itraconazole	■	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Ketoconazole	■	●	■	◆	●	●	◆	◆	◆	◆	◆
Miconazole	△	◆	◆	△	◆	◆	◆	◆	◆	◆	◆
Nystatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Posaconazole	■	◆	■	◆	●	●	◆	◆	◆	◆	◆
Terbinafine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Voriconazole	■	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Antihaemorrhagics											
Avatrombopag	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Eltrombopag	■	●	●	◆	◆	◆	◆	◆	△	●	◆
Tranexamic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antihistamines											
Astemizole	◆	◆	■	◆	●	●	◆	◆	◆	◆	◆
Bilastine	■	■	△	■	■	◆	◆	◆	■	■	◆
Cetirizine	△	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorphenamine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Clemastine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Desloratadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diphenhydramine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doxylamine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ebastine	◆	■	■	◆	■	■	◆	◆	◆	◆	◆
Fexofenadine	■	◆	△	◆	■	■	◆	◆	◆	△	◆
Hydroxyzine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levocetirizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loratadine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Promethazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Terfenadine	◆	◆	■	◆	●	●	◆	◆	◆	◆	◆
Antimigraine Agents											
Almotriptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dihydroergotamine	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Eletriptan	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Eptinezumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erenumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ergotamine	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Fremanezumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Frovatriptan	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Galcanezumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylergonovine	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Naratriptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pizotifen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rizatriptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sumatriptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zolmitriptan	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Antiprotozoals											
Amodiaquine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Artemether	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Artesunate	△	△	◆	◆	■	■	◆	◆	△	■	◆
Atovaquone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Chloroquine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dihydroartemisinin	△	△	◆	◆	■	■	◆	◆	△	■	◆
Doxycycline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Halofantrine	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Hydroxychloroquine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lumefantrine	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Mefloquine	■	◆	■	■	■	■	◆	◆	◆	■	◆
Nitazoxanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentamidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piperaquine	△	△	△	◆	■	■	◆	◆	◆	◆	◆
Primaquine	△	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Proguanil	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Pyrimethamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Quinine	■	△	■	■	■	■	◆	◆	◆	■	◆
Sodium stibogluconate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfadoxine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antipsychotics/neuroleptics											
Amisulpride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aripiprazole	◆	■	■	◆	■	■	◆	◆	◆	◆	◆
Asenapine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Brexpiprazole	◆	△	△	△	■	■	◆	◆	◆	◆	■
Cariprazine	◆	△	△	△	●	●	◆	◆	◆	◆	■
Chlorpromazine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Chlorprothixene	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clozapine	◆	◆	■	◆	■	■	◆	◆	◆	◆	■
Flupentixol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Fluphenazine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Haloperidol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Iloperidone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Levomepromazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loxapine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lurasidone	◆	△	△	◆	●	●	◆	◆	◆	◆	◆
Melperone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Olanzapine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Paliperidone	■	◆	■	■	■	■	◆	◆	■	■	◆
Perazine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Periciazine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Perphenazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pimozide	◆	●	●	●	●	●	◆	◆	◆	◆	◆
Pipotiazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prochlorperazine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Promazine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Quetiapine	◆	■	■	◆	●	●	◆	◆	◆	◆	◆
Risperidone	△	◆	△	△	■	■	◆	◆	△	△	◆
Sulpiride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tiapride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trifluoperazine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Ziprasidone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Zuclopentixol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Antivirals											
Aciclovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amantadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Ansuvimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brincidofovir	◆	●	■	◆	■	■	◆	◆	■	■	■
Brivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cidofovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Favipiravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Foscarnet	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Letermovir	△	△	■	■	●	●	△	■	■	■	■
Molnupiravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nirmatrelvir/ritonavir	◆	●	●	◆	■	■	◆	◆	◆	■	◆
Oseltamivir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Palivizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Remdesivir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rimantadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sotrovimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tecovirimat	△	△	◆	◆	△	△	◆	◆	△	△	◆
Tixagevimab/cilgavimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valaciclovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zanamivir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Anxiolytics/hypnotics/sedatives											
Alprazolam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Amobarbital	●	●	●	●	●	●	●	●	●	●	◆
Bromazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromperidol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Buspirone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Chlordiazepoxide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clobazam	◆	◆	◆	◆	■	■	◆	◆	△	△	◆
Clorazepate	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clotiapine	◆	△	△	△	■	■	◆	◆	◆	◆	◆
Daridorexant	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Diazepam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Estazolam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Flurazepam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lemborexant	◆	■	■	◆	●	●	■	◆	◆	◆	◆
Lorazepam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lormetazepam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Midazolam (oral)	◆	■	◆	◆	●	●	◆	◆	◆	◆	◆
Midazolam (parenteral)	◆	■	◆	◆	■	■	◆	◆	◆	◆	◆
Nitrazepam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Oxazepam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Quazepam	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Temazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Triazolam	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Zaleplon	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Zolpidem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zopiclone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Beta Blockers											
Atenolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisoprolol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Carvedilol	■	◆	■	■	■	■	◆	◆	■	■	■
Celiprolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Labetalol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Metoprolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nebivolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxprenolol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Pindolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propranolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sotalol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Timolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisphosphonates											
Alendronic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clodronate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ibandronic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pamidronate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Risedronate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zoledronic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bronchodilators											
Aclidinium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aminophylline	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Formoterol	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Indacaterol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ipratropium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Montelukast	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Omalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Reslizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Salbutamol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Salmeterol	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Theophylline	◆	◆	■	◆	■	■	◆	◆	◆	◆	◆
Tiotropium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Umeclidinium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vilanterol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Calcium channel blockers											
Amlodipine	■	◆	◆	■	■	■	◆	◆	◆	◆	◆
Diltiazem	■	◆	■	■	■	■	◆	◆	■	■	◆
Felodipine	■	■	◆	■	■	■	◆	◆	◆	◆	◆
Nicardipine	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Nifedipine	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Nisoldipine	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Nitrendipine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Verapamil	◆	◆	■	◆	■	■	◆	◆	◆	■	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Cancer Therapies											
Abiraterone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acalabrutinib	◆	■	■	■	●	●	◆	◆	■	■	■
Afatinib	■	■	■	■	■	■	■	◆	■	■	◆
Alectinib	◆	◆	◆	◆	△	△	◆	◆	◆	◆	■
Alpelisib	■	■	■	■	■	■	■	◆	■	■	■
Amivantamab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anastrozole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Apalutamide	●	●	●	■	●	●	■	■	●	●	◆
Asciminib	◆	●	■	◆	■	■	◆	◆	◆	●	■
Asparaginase	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atezolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	△
Avapritinib	◆	■	■	◆	●	●	◆	◆	◆	◆	■
Avelumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Axitinib	◆	△	△	◆	●	●	◆	◆	◆	◆	■
Azacitidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Belantamab mafodotin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	△
Bendamustine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	■
Bevacizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Bexarotene	■	■	△	◆	●	●	◆	◆	■	■	■
Bicalutamide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Binimetinib	◆	◆	◆	◆	■	■	■	◆	◆	◆	◆
Blinatumomab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Bortezomib	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Bosutinib	◆	■	■	◆	●	●	◆	◆	◆	◆	■
Brentuximab vedotin	◆	△	△	◆	■	■	◆	◆	◆	△	■
Brigatinib	△	■	△	◆	■	■	◆	◆	△	△	■
Cabozantinib	◆	◆	◆	◆	■	■	■	◆	◆	◆	◆
Capecitabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Capmatinib	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Carboplatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Carfilzomib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	△
Cedazuridine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cemiplimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	△
Ceritinib	■	●	■	■	●	●	◆	◆	■	■	■
Cetuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorambucil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Cisplatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Cladribine (IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Cobimetinib	■	◆	■	■	●	●	◆	◆	■	■	■
Crizotinib	◆	◆	◆	◆	●	●	◆	◆	◆	◆	■
Cyclophosphamide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Cytarabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Dabrafenib	●	●	■	●	●	●	●	●	●	●	■
Daratumumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Dasatinib	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Decitabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Dinutuximab beta	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	△
Docetaxel	■	■	■	◆	■	■	◆	◆	△	■	■
Dostarlimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Doxorubicin	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	■
Durvalumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	△
Duvelisib	■	●	◆	◆	■	■	◆	◆	◆	◆	■
Elotuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elranatamab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Encorafenib	●	●	■	◆	●	●	◆	◆	◆	●	■
Enfortumab vedotin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Enzalutamide	●	●	■	◆	●	●	◆	◆	●	●	◆
Epcoritamab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Epirubicin	◆	◆	◆	◆	■	■	△	◆	◆	◆	◆
Erlotinib	■	■	■	■	●	●	◆	◆	■	■	◆
Estramustine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etoposide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Everolimus	■	■	■	■	●	●	◆	◆	■	■	◆
Exemestane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fludarabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Fluorouracil (5-FU)	◆	◆	◆	△	◆	◆	◆	△	△	△	■
Garadacimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gefitinib	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Gemcitabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Gemtuzumab ozogamicin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Glofitamab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Cancer Therapies continued											
Hydroxyurea (Hydroxycarbamide)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Ibrutinib	■	■	■	◆	●	●	◆	◆	◆	◆	△
Idarubicin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Idelalisib	■	■	■	■	●	●	■	◆	■	■	△
Imatinib	◆	■	■	◆	■	■	◆	◆	■	●	■
Inotuzumab ozogamicin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Ipilimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Irinotecan	■	■	■	■	■	■	◆	◆	■	●	■
Isatuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Ixazomib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Lapatinib	■	■	■	■	■	■	■	◆	■	●	◆
Letrozole	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Loncastuximab tesirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Medroxyprogesterone (oncology)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Mercaptopurine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Mesna	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methotrexate	■	■	■	◆	△	△	■	◆	■	●	■
Mitoxantrone	■	■	■	■	■	■	■	◆	■	●	■
Mogamulizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nilotinib	■	■	■	◆	■	■	◆	◆	■	●	◆
Niraparib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Nivolumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Obinutuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ofatumumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Olaparib	◆	●	■	■	■	■	◆	◆	◆	■	△
Olaratumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Osimertinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Oxaliplatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Paclitaxel	◆	■	■	◆	■	■	◆	◆	◆	◆	■
Panitumumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Panobinostat	◆	●	■	■	■	■	◆	◆	△	●	△
Pertuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Polatuzumab vedotin	◆	△	△	◆	■	■	◆	◆	◆	△	■
Pomalidomide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Ponatinib	◆	■	■	◆	■	■	■	◆	◆	◆	■
Ramucirumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Retifanlimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Ribociclib	■	●	■	■	●	●	◆	◆	◆	●	■
Rituximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Rucaparib	■	■	■	■	■	■	■	◆	■	■	■
Ruxolitinib	◆	△	△	△	■	■	◆	◆	◆	◆	■
Sacituzumab govitecan	◆	◆	◆	◆	●	●	◆	◆	◆	◆	■
Selpercatinib	■	△	△	◆	■	●	◆	◆	◆	◆	◆
Sotorasib	■	■	△	◆	●	●	◆	◆	■	■	■
Sunitinib	◆	◆	■	◆	■	■	■	◆	◆	◆	■
Talazoparib	■	■	■	■	■	■	■	◆	■	■	■
Tamoxifen	△	△	◆	◆	■	■	◆	◆	△	△	◆
Tegafur/Gimeracil/Oteracil	◆	◆	◆	△	◆	◆	◆	△	△	△	■
Temsirolimus	■	■	■	■	■	■	◆	◆	■	■	◆
Tepotinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thioguanine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Tisotumab vedotin	◆	△	△	◆	■	■	◆	◆	◆	△	■
Tivozanib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Topotecan (IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Topotecan (oral)	■	■	■	■	■	■	■	◆	■	●	■
Trametinib	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Trastuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Trastuzumab deruxtecan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trastuzumab emtansine	◆	■	◆	◆	●	●	◆	◆	◆	◆	■
Tremelimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trifluridine/tipiracil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Vemurafenib	■	●	■	◆	●	●	◆	◆	■	■	△
Venetoclax	◆	■	■	◆	●	●	■	◆	◆	◆	■
Vinblastine	◆	■	●	■	■	■	◆	◆	■	●	■
Vincristine	◆	■	●	■	■	■	◆	◆	■	●	■
Vinorelbine	■	■	■	■	■	■	◆	◆	■	■	■
Zolbetuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Contraceptives and hormone replacement											
Conjugated Estrogens	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Desogestrel (POP)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Desogestrel/ethinylestradiol (COC) (>20 µg)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Desogestrel/ethinylestradiol (COC) (≤20 µg)	◆	◆	■	◆	●	●	◆	◆	◆	●	◆
Dienogest	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Dienogest/estradiol valerate (COC)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Drospirenone (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone/estradiol (HRT)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Drospirenone/Ethinyl-estradiol (COC) (>20 µg)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Drospirenone/Ethinyl-estradiol (COC) (≤20 µg)	◆	◆	■	◆	●	●	◆	◆	◆	●	◆
Dydrogesterone/estradiol (HRT)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Estradiol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ethinylestradiol (>20 µg)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Ethinylestradiol (≤20 µg)	◆	◆	■	◆	●	●	◆	◆	◆	●	◆
Etonogestrel (implant)	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Etonogestrel (vaginal ring)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Gestodene/ethinylestradiol (COC) (>20 µg)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Gestodene/ethinylestradiol (COC) (≤20 µg)	◆	◆	■	◆	●	●	◆	◆	◆	●	◆
Levonorgestrel (Emergency Contraception)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (HRT)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Levonorgestrel (implant)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (IUD)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel/ethinyl-estradiol (COC) (>20 µg)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Levonorgestrel/ethinyl-estradiol (COC) (≤20 µg)	◆	◆	■	◆	●	●	◆	◆	◆	●	◆
Medroxyprogesterone (depot)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone/conjug ated estrogens (HRT)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Medroxyprogesterone/ estradiol (HRT)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Micronized progesterone (HRT)	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Norelgestromin/ ethinylestradiol (patch)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Norethisterone (Norethindrone) (depot injection)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone) (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/estradiol (HRT)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/ ethinylestradiol (COC)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Norethisterone (Norethindrone)/ mestranol (COC)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Norgestimate/ ethinylestradiol (COC)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Norgestrel/conjugated estrogens (HRT)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Norgestrel/ethinylestradiol (COC)	◆	◆	●	◆	●	●	◆	◆	◆	●	◆
Testosterone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Erectile dysfunction agents											
Sildenafil	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Vardenafil	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Yohimbine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Gastrointestinal agents											
Aluminium hydroxide	◆	◆	◆	■	◆	◆	■	△	■	■	◆
Alverine citrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	■	◆	◆	■	△	■	■	◆
Aprepitant	△	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	△	◆	◆	△	◆	△	△	◆
Cimetidine	△	◆	△	■	◆	◆	■	◆	■	■	◆
Cisapride	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Cyclizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dantron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Docusate sodium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Domperidone	◆	◆	■	◆	●	●	◆	◆	◆	◆	◆
Droperidol	◆	◆	■	◆	■	■	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	△	■	△	△	△	◆	■	■	◆
Famotidine	◆	◆	△	■	◆	◆	■	◆	■	■	◆
Granisetron	◆	△	△	◆	■	■	◆	◆	◆	◆	◆
Hyoscine (Scopolamine)	◆	△	△	△	■	■	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine hydrobromide (Scopolamine hydrobromide)	◆	△	△	△	■	■	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lafutidine	◆	◆	△	■	△	△	■	◆	■	■	◆
Lansoprazole	◆	◆	△	■	△	△	△	◆	■	■	◆
Linaclotide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loperamide	■	△	△	■	■	◆	◆	◆	◆	△	◆
Lubiprostone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Macrogol	△	△	△	△	△	△	△	△	△	△	△
Mebeverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mesalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylcellulose	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naldemedine	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Naloxegol	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Nizatidine	◆	◆	△	■	◆	◆	■	◆	■	■	◆
Omeprazole	◆	◆	△	■	△	△	△	◆	■	■	◆
Ondansetron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	△	■	△	△	△	◆	■	■	◆
Prucalopride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	△	■	△	△	△	◆	■	■	◆
Ranitidine	◆	◆	△	■	◆	◆	■	◆	■	■	◆
Roxatidine	◆	◆	△	■	◆	◆	■	◆	■	■	◆
Senna	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Simeticone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfasalazine	◆	◆	■	◆	■	■	◆	◆	■	●	◆
Trimebutine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vonoprazan	◆	◆	△	■	◆	◆	△	◆	■	■	◆
HCC Therapies											
Atezolizumab + bevacizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Lenvatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	△
Pembrolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Regorafenib	◆	△	△	■	●	●	■	◆	■	■	△
Sorafenib	◆	■	◆	◆	■	■	◆	◆	◆	◆	△
Hepatitis B Drugs											
Adefovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Entecavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Peginterferon alfa-2a	◆	■	■	■	■	■	◆	◆	■	■	◆
Peginterferon alfa-2b	◆	■	■	■	■	■	◆	◆	■	■	◆
Telbivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir alafenamide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	■	◆	◆	◆	◆	■	■	◆
Hepatitis C Directly Acting Antivirals (DAAs)											
Daclatasvir		●	●	◆	●	●	●	◆	●	●	◆
Elbasvir/Grazoprevir	●		●	●	●	●	●	◆	●	●	◆
Glecaprevir/Pibrentasvir	●	●		●	●	●	●	◆	●	●	◆
Ledipasvir/Sofosbuvir	◆	●	●		●	●	●	●	●	●	◆
OBV/PTV/r	●	●	●	●		n/a	●	●	●	●	◆
OBV/PTV/r + DSV	●	●	●	●	n/a		●	◆	●	●	◆
Ravidasvir	●	●	●	●	●	●		◆	●	●	◆
Ribavirin	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	
Sofosbuvir	◆	◆	◆	●	●	◆	◆		●	●	◆
SOF/Velpatasvir	●	●	●	●	●	●	●	●		●	◆
SOF/Velpatasvir/Voxilaprevir	●	●	●	●	●	●	●	●	●		■
Hepatitis D Directly Acting Antivirals (DAAs)											
Bulevirtide	◆	△	△	◆	●	●	◆	◆	◆	△	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Herbals/Supplements/Vitamins											
Aloe vera	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ashwagandha (Withania somnifera)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Black cohosh	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium carbonate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Collagen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (*U. tomentosa*)	■	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Choline alfoscerate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enteral feeds	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eucalyptus globulus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginger (*Z. officinale*)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginseng	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Goldenseal (*H. canadensis*)	■	■	■	◆	■	■	◆	◆	◆	◆	◆
Grape seed extract	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Grapefruit juice	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Green tea (*C. sinensis*)	△	△	△	◆	△	△	◆	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydroxocobalamin (Vitamin B12)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Inula racemosa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Kava kava	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
L-lysine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Menthol	△	△	△	◆	△	△	◆	◆	◆	◆	◆
Milk thistle	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mucuna pruriens	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Niacin (Vitamin B3)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oral nutritional supplements	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oregano oil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyridoxine (Vitamin B6)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Retinol (Vitamin A)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riboflavin (Vitamin B2)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Saw Palmetto (*S. repens*)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
St John's wort	●	●	●	●	●	●	●	●	●	●	◆
Thiamine (Vitamin B1)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Turmeric (curcumin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valerian	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin E	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
HIV Drugs											
Entry/Integrase Inhibitors											
Albuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bictegravir/FTC/TAF	◆	◆	△	◆	■	■	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (LA)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/3TC	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/ABC/3TC	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/rilpivirine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Elvitegravir/cobi /FTC/TAF	■	●	◆	◆	●	●	◆	◆	◆	◆	◆
Elvitegravir/cobi/FTC/TDF	■	●	◆	■	●	●	◆	◆	■	■	◆
Enfuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fostemsavir	◆	●	△	△	△	△	◆	△	△	■	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenacapavir	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Maraviroc	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
NNRTIs											
Dapivirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Doravirine/3TC/TDF	◆	◆	◆	■	△	△	◆	◆	■	■	◆
Efavirenz	■	●	●	◆	●	●	◆	◆	●	●	◆
Etravirine	■	●	●	◆	●	●	◆	◆	●	●	◆
Nevirapine	■	●	●	◆	●	●	◆	◆	●	●	◆
Rilpivirine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Rilpivirine/FTC/TAF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
NRTIs											
Abacavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Didanosine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Emtricitabine (FTC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine + TAF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Emtricitabine + TDF	◆	◆	◆	■	◆	◆	◆	◆	■	■	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Stavudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Tenofovir-DF (TDF)	◆	◆	◆	■	◆	◆	◆	◆	■	■	◆
Zidovudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Protease Inhibitors											
Atazanavir + ritonavir	■	●	●	◆	●	●	◆	◆	◆	●	■
Atazanavir alone	◆	●	●	◆	■	■	◆	◆	◆	●	■
Atazanavir/cobicistat	■	●	●	◆	●	●	◆	◆	◆	●	■
Darunavir + ritonavir	◆	●	●	◆	■	■	◆	◆	◆	■	◆
Darunavir/cobicistat	◆	●	●	◆	●	●	◆	◆	◆	◆	◆
Darunavir/cobi/FTC/TAF	◆	●	●	◆	●	●	◆	◆	◆	◆	◆
Fosamprenavir	■	●	●	◆	■	■	◆	◆	◆	●	◆
Indinavir	■	●	●	◆	●	●	◆	◆	◆	●	◆
Lopinavir	◆	●	●	■	●	●	◆	◆	◆	●	◆
Ritonavir	■	●	●	◆	●	●	◆	◆	◆	■	◆
Tipranavir	■	●	●	●	●	●	◆	●	●	●	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Hypertension/heart failure agents											
Acebutolol	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Aliskiren	■	◆	●	■	●	●	◆	◆	◆	■	◆
Ambrisentan	■	◆	■	◆	■	■	◆	◆	◆	■	◆
Amiloride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benazepril	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bosentan	■	●	■	◆	●	●	◆	◆	■	■	◆
Bumetanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Candesartan	◆	△	△	◆	◆	◆	◆	◆	◆	△	◆
Captopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorothiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlortalidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clevidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Doxazosin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Enalapril	◆	◆	■	◆	■	■	◆	◆	◆	■	◆
Eplerenone	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Epoprostenol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fosinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indapamide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Irbesartan	◆	◆	■	■	■	■	◆	◆	◆	△	◆
Isradipine	■	■	■	■	■	■	◆	◆	◆	■	◆
Ivabradine	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Lacidipine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lercanidipine	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Lisinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Losartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Macitentan	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Methyldopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Olmesartan	■	◆	■	◆	■	■	◆	◆	◆	■	◆
Perindopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prazosin	◆	■	■	◆	◆	◆	◆	◆	■	■	◆
Quinapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ramipril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranolazine	■	■	■	■	●	●	◆	◆	◆	■	◆
Rilmenidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riociguat	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Sacubitril/valsartan	■	●	■	◆	■	■	◆	◆	◆	■	◆
Selexipag	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Sildenafil	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Sodium nitroprusside	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Spironolactone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Telmisartan	◆	◆	■	◆	■	■	◆	◆	◆	■	◆
Torasemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trandolapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Treprostinil	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Valsartan	■	◆	◆	◆	■	■	◆	◆	◆	■	◆
Xipamide	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Zofenopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Illicit/Recreational											
Alcohol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Bromazolam	◆	△	△	◆	■	■	◆	◆	◆	◆	◆
Cannabis	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Carfentanil	◆	■	■	◆	●	●	◆	◆	◆	◆	◆
Cocaine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ecstasy (MDMA)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Etizolam	◆	△	△	◆	●	●	◆	◆	◆	◆	◆
Fentanyl (Recreational)	◆	△	△	◆	■	■	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ketamine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Mephedrone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Methamphetamine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Methaqualone	◆	△	△	◆	●	●	◆	◆	◆	◆	◆
Nicotine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nitazenes	◆	△	△	△	●	●	△	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phencyclidine (PCP)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Xylazine	◆	△	△	◆	●	●	◆	◆	◆	◆	◆
Immunosuppressants											
Abatacept	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Adalimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Alemtuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anakinra	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Apremilast	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azathioprine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Baricitinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Basiliximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Belimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bimekizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brodalumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Canakinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Ciclosporin	△	●	■	△	■	■	△	△	△	●	◆
Cladribine (oral)	■	■	■	■	■	■	■	■	■	■	●
Eculizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etanercept	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fingolimod	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Golimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Guselkumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Infliximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Ixekizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirikizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mycophenolate	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Pirfenidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ravulizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Risankizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sarilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Secukinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Siltuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Sirolimus	◆	■	■	◆	●	●	◆	◆	■	■	◆
Tacrolimus	△	■	■	△	●	●	△	△	△	△	◆
Tildrakizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tocilizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Tralokinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ublituximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Upadacitinib	◆	◆	◆	◆	■	■	◆	◆	△	△	■
Ustekinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vedolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Lipid Lowering Agents											
Alirocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atorvastatin	■	■	●	■	●	●	■	◆	■	■	◆
Bempedoic acid	◆	●	■	◆	△	△	◆	◆	◆	◆	◆
Evolocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	■	◆	■	■	◆	◆	◆	■	◆
Fish oils	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvastatin	■	■	■	■	■	■	■	◆	■	●	◆
Gemfibrozil	◆	■	■	◆	◆	●	◆	◆	◆	◆	◆
Icosapent ethyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lovastatin	■	■	●	■	●	●	■	◆	■	●	◆
Omega-3-6-9 fatty acids	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pitavastatin	■	◆	■	■	■	■	■	◆	■	●	◆
Pravastatin	■	◆	■	■	■	■	■	◆	◆	■	◆
Rosuvastatin	■	■	■	●	■	■	■	◆	■	●	◆
Simvastatin	■	■	●	■	●	●	■	◆	■	●	◆
Other Drugs											
Abaloparatide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acamprosate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acetazolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Activated charcoal	△	△	△	△	△	△	△	△	△	△	△
Allopurinol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Atomoxetine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bamlanivimab/ Etesevimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betahistine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benzonatate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bimatoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brimonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Brolucizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Burosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcitonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium carbimide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium resonium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cannabidiol (CBD)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Carbimazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carisoprodol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Casirivimab/imdevimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilostazol	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Colchicine	■	■	■	■	■	■	◆	◆	■	■	◆
Colestyramine	△	△	△	△	△	△	△	△	△	△	△
Conivaptan	●	◆	◆	◆	●	●	◆	◆	◆	◆	◆
COVID-19 vaccines	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Crizanlizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclobenzaprine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Cyproterone acetate	△	△	△	◆	■	■	◆	◆	◆	◆	■
Cytisine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Darbepoetin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Deferiprone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Denosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamfetamine	△	△	△	△	■	■	◆	◆	△	△	◆
Dextromethorphan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Donepezil	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Dorzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dotinurad	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eliglustat	◆	■	■	◆	●	●	◆	◆	◆	◆	◆
Elinzanetant	◆	△	△	◆	●	●	◆	◆	◆	◆	◆
Emicizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epoetin alfa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etelcalcetide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fampridine (Dalfampridine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Faricimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fezolinetant	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flibanserin	◆	■	■	◆	●	●	◆	◆	◆	◆	◆
Gadopentetate (gadolinium)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glucose monohydrate (IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glycerol phenylbutyrate	△	△	◆	◆	△	△	◆	◆	△	△	◆
Goserelin acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Guanfacine	◆	△	△	△	■	■	◆	◆	◆	◆	◆
Idarucizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Influenza vaccine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; RDV, Ravidasvir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Other Drugs continued											
Interferon beta	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isotretinoin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lanadelumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanreotide	△	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Lebrikizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Leuprorelin acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levothyroxine	△	◆	◆	◆	■	■	◆	◆	◆	◆	■
Lisdexamfetamine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Lofexidine	△	△	△	△	△	△	◆	◆	△	△	◆
Lumacaftor/Ivacaftor	●	●	■	■	●	●	◆	●	●	●	◆
Magnesium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maralixibat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mepolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methimazole (Thiamazole)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Methylphenidate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Midodrine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Modafinil	■	●	■	■	■	■	●	■	■	■	◆
Naftidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nalmefene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nemolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nusinersen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orforglipron	◆	◆	■	◆	●	●	◆	◆	■	■	◆
Orlistat	△	△	△	△	△	△	◆	△	△	△	△
Pancreatic enzymes	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Penicillamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phentermine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propylthiouracil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Protamine sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ranibizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Resmetirom	●	●	●	◆	●	●	◆	◆	■	●	◆
Romosozumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rozanolixizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sevelamer	△	◆	△	△	△	△	△	△	△	△	△
Sodium zirconium cyclosilicate	◆	◆	◆	△	◆	◆	△	◆	△	△	◆
Sotatercept	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Strontium ranelate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tetrabenazine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Thalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Triptorelin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/ GZR	G/P	LED/ SOF	OBV/ PTV/r	OBV/ PTV/r +DSV	RDV	SOF	SOF/ VEL	SOF/ VEL/ VOX	RBV
Oxytocics											
Ergometrine (ergonovine)	◆	■	■	■	●	●	◆	◆	◆	◆	◆
Mifepristone	△	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Parkinsonism Agents											
Benzatropine (Benztropine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levodopa	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pramipexole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Procyclidine	◆	◆	◆	◆	△	△	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Ropinirole	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Selegiline	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Trihexyphenidyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
PBC Agents											
Bezafibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elafibranor	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fenofibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Obeticholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Seladelpar	■	■	■	■	■	■	■	◆	■	■	◆
Ursodeoxycholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Steroids											
Beclometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Budesonide	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Ciclesonide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamethasone ≤16 mg	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Dexamethasone >16 mg	■	■	△	△	■	■	■	◆	■	■	◆
Fludrocortisone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Flunisolide	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Methylprednisolone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Mometasone	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Prednicarbate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Triamcinolone	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Urological Agents											
Alfuzosin	◆	◆	◆	◆	●	●	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Finasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirabegron	◆	△	◆	◆	■	■	◆	◆	◆	◆	◆
Oxybutynin	◆	△	△	◆	■	■	◆	◆	◆	◆	◆
Propiverine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Silodosin	■	■	■	■	●	●	◆	◆	■	■	◆
Sodium bicarbonate (oral)	◆	◆	◆	■	◆	◆	■	◆	■	■	◆
Solifenacin	◆	△	△	◆	■	■	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Trospium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Using a saved or printed version? Click or scan to check for updates.

For personal use only. Not for distribution.

For personal use only. Not for distribution.

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.